Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes

By sjmartinez • March 28, 2023

Epistola R, Sperandio R, Wainberg Z, Iqbal S, Chao J. Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes. Cancer Manag Res. 2023 Mar 18;15:265-275. doi: 10.2147/CMAR.S341468. PMID: 36969544; PMCID: PMC10032141.

Tags: gastric cancer, gastroesophageal junction cancer, Hematology/Oncology, immune checkpoint inhibition, immunotherapy, PD-L1, Publications

Finn RS, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Cheng AL, Galle PR, Kaneko[...]

A Two-Stage Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Ec-18 in Altering the Severity and Course of Oral Mucositis Secondary to Chemoradiation Therapy for Squamous Cell Cancers of the Head and Neck

Henson C, Clayburgh D, Lee A, Wong D, Kudrimoti M, Lee S, Kalman N, Rao K, Sohn KY, Crawford J, Villa A, Sonis S. A[...]

Basic rules to respond to PD-1 blockade cancer immunotherapy

Ribas A. Basic rules to respond to PD-1 blockade cancer immunotherapy. J Immunother Cancer. 2025 May 26;13(5):e012096. doi: 10.1136/jitc-2025-012096. PMID: 40425230.